key: cord-0923426-m669k5fo
authors: Fei, Yiming; Xu, Hainan; Zhang, Xingyue; Musa, Salihu S.; Zhao, Shi; He, Daihai
title: Seroprevalence and infection attack rate of COVID-19 in Indian cities
date: 2022-03-10
journal: Infect Dis Model
DOI: 10.1016/j.idm.2022.03.001
sha: ab89c7586d21e28db0d6f600b9603d34d794b409
doc_id: 923426
cord_uid: m669k5fo

OBJECTIVES: Serological surveys were used to infer the infection attack rate in different populations. The sensitivity of the testing assay, Abbott, drops fast over time since infection which make the serological data difficult to interpret. In this work, we aim to solve this issue. METHODS: We collect longitudinal serological data of Abbott to construct a sensitive decay function. We use the reported COVID-10 deaths to infer the infections, and use the decay function to simulate the seroprevalence and match to the reported seroprevalence in 12 Indian cities. RESULTS: Our model simulated seroprevalence match the reported seroprevalence in most (but not all) of the 12 Indian cities we considered. We obtain reasonable infection attack rate and infection fatality rate for most of the 12 Indian cities. CONCLUSIONS: Using both reported COVID-19 deaths data and serological survey data, we infer the infection attack rate and infection fatality rate with increased confidence.

that the control in India was a success until a major second wave hit the country and causing 50 large number of mortalities. But the reported deaths per capita is still relatively low compared 51 to other Western countries. Velumani et al. (Velumani et al. 2021 ) studied seroprevalence in 52 12 Indian cities from July to December 2020. Their result showed two distinct patterns: a 53 wave pattern, e.g., Mumbai and Pune, and a monotone increasing pattern, e.g. Delhi and 54 others. These patterns were driven by the underlying COVID-19 pandemic in each city. 55

However, the other key drivers are the use of multiple brands of antibody testing machines 56 (or assays): in particular Abbott and non-Abbott, e.g., Roche. Abbott and Roche are widely 57 used serological testing devices in the market. The method of Abbott SARS-CoV-2 IgG assay 58 is acridinium-labelled anti-human IgG. Roche used ruthenium-labelled and biotin-conjugated 59 N protein to perform the Anti-SARS-CoV total antibody assay. Velumani et al. (Velumani et 60 al. 2021 ) highlighted that two machines were used in this study, without specifying which 61 city used which one. Presumably, the Abbott was used in these wave-pattern cities while 62

Roche was in others (we explain the reason later). The two machines have very different 63 'decay rates' as found in (Muecksch et al. 2021) . With data from (Muecksch et al. 2021 ), 64 Figure 1 shows a comparison of the sensitivity of Abbott vs Roche. 65

We observed that Abbott showed a very rapid drop in sensitivity over time for confirmed infections after RT-PCR confirmation (or onset of symptom for symptomatic cases 67 after RT-PCR confirmed). While the sensitivity of Roche is stable. Moreover, as explained in 68 the method (later section). The seroprevalence obtained with Roche would be much closer to 69 the infection attack rate (IAR, defined as the cumulative proportion of the infected 70 population), which shows a monotone increasing pattern. Since the antibody level of infected 71 individual will gradually wane over time which causing the sensitivity of the testing drop (an 72 infected person became seronegative), the seroprevalence will be lower than the attack rate 73

The relationship between COVID-19 deaths and seroprevalence 99

Following (He et al. 2021) , we denote the daily COVID-19 seroprevalence as 100 (proportion of population showing seropositive / antibody positive at a given day), daily sero-101 conversion as + (sero-negative individual turns sero-positive), daily sero-reversion as − 102 (sero-positive individual turns sero-negative due to antibody waning), then we have the 103

Assuming initially all these are zero, this can be written as 106

Denote ( ) as the sensitivity decay function which is given in Figure 2b . 108

i.e., the convolution (here we rewrite the summation in the above equation into integral 110 fashion) between ( ) and ( ), where ( ) is the time series of daily new cases, is the 111 size of the population. But, typically ( ) is not very reliable due to time-varying testing 112 policy and testing effort and a significant amount of asymptomatic cases. Nonetheless, the 113 daily COVID-19 deaths are available ((by law in many regions) and relatively reliable than 114 reported cases. We denote as the infection fatality ratio (IFR). Thus, the daily new cases 115 are roughly given as ( ) = ( + 14)/ . We assume a delay between deaths and case 116 confirmation (ie, symptom onset for symptomatic cases) of 14 days. The seroprevalence on 117 day is given: Thus given ( ) and death data, we can get ( ) and ( ) easily if is known. However, 123 estimates vary in previous studies, across locations and rely on the efforts of COVID-19 124 cases and deaths reporting. We argue that we may estimate by matching ( ) to reported 125 seroprevalences at different time points. If the matching is acceptable, then we may accept 126 the reported seroprevalences (given that it was Abbott based), and we immediately obtain the 127 IAR and . We propose the following approach to match ( ): we calculate the sum of 128 squared errors (SSE) between ( ) and reported seroprevalence on six data points from July 129 to Dec, 2020 for a range of , and choose the which attains the smallest SSE. 130

Figure 3 and Table 1 shows the main results, where we applied our method to 12 large 132

Indian cities. Since we do not know the IFR, we align the reconstructed seroprevalence (blue 133 dashed curve) and serological survey (black curve with circles) using the approach given in 134 Method; this alignment will yield an IFR , which is applied to the whole reconstructed 135 seroprevalence and the IAR curve (red curve). The reconstructed and observed 136 seroprevalence matched reasonably well for most cities, where Abbott is likely used for most 137 of the period. This works fine for most cities except for a few cities, e.g., Ahmedabad. In 138

Ahmedabad, the serological survey went up too fast than the increase in IAR. Thus, some 139 mechanism unknown might occur (e.g. non-Abbott or inconsistence assay or inconsistence in 140 death reports) which affected the serological survey or dramatic changing in COVID-19 141 death reporting process. 142 Chennai, and Coimbatore. The reconstructed seroprevalence also successfully matched with 150 the trend of serological surveys in Kolkata, Nagpur, and Visakhapatnam. The method failed 151 in the rest, where a non-Abbott (or change of testing assay) was likely used. We do not have 152 sufficient data to reconstruct the sensitivity decay curve of Roche. Once it is available, a 153 similar approach can be made readily (we leave for further study). In Figures 1&2, we 154 assume a peak sensitivity of 100% for Abbott, which could be too ideal (since the data 155 collected was mainly symptomatic cases). For asymptomatic cases, the peak sensitivity could 156 be as low as 80%. However, as long as the shape of the decay curve is kept, a factor (80%) on 157 the whole decay curve can be translated into a factor in the IFR. The reciprocal of the IFR 158 and the sensitivity decay rate appear in a product form in our IAR and seroprevalence 159 J o u r n a l P r e -p r o o f equation. Therefore, it would not change our final estimate of IAR and seroprevalence when 160 the factor is in IFR or in the decay rate. 161

Moreover, we formulated a simple method to reconstruct the IAR and estimate the 162 seroprevalence of COVID-19 deaths in India. Our simple approach works well in most of 12 163

Indian cities where serological survey data are available. We achieved this without knowing 164 which cities used Abbott (we know Abbott was used in Mumbai). In some cities where our 165 method did not yield a reasonable fit were likely due to the use of a non-Abbott (e.g. Roche) 166 or mixing of different testing assays. According to the available information, we observed proportion of the overall population is still susceptible to COVID-19 infection (Murhekar, 185 Bhatnagar, Selvaraju, et al. 2021) . This further highlighted that the virus's transmission could 186 likely continue in most cities in India until the herd immunity threshold is reached. The herd 187 immunity can be achieved either by previous exposure to the virus or through vaccination 188 (Britton, Ball, and Trapman 2020; Murhekar, Bhatnagar, Selvaraju, et al. 2021) The IFR estimates in Table 1 are low. On one hand, many serological studies found 195 that a very large proportion of the population has been infected. On the other hand, the 196 reported deaths is low (may or may not be due to under reporting). These two factors led to a 197 seemingly low IFR in India. Banaji (Banaji 2021) found a lower bound IFR in Mumbai at 198 0.1% with consideration of excess deaths (additional to reported COVID-deaths), which is 199 not very far from our estimates here. Here we used reported COVID-19 deaths only, which 200 could lead to a low IFR. 201

We estimated the seroprevalence rate, and reconstructed an IAR in 12 Indian cities and 202 found a reasonable seropositivity rate to SARS-CoV-2 in most cities. We showed that the 203 seroprevalence rate was lower than the reconstructed IAR, which is a monotone-increasing 204 function due to antibody waning. We aligned the reconstructed seroprevalence and 205 serological survey to yield an IFR, which was applied to both the reconstructed 206 seroprevalence and the IAR curve. These results are in line with previous estimates, which 207 J o u r n a l P r e -p r o o f highlighted the seroprevalence of COVID-19 deaths to be high in large cities; as well as with 208 a limited number of serological surveys in more randomly selected populations (George et al. 209 2021; Velumani et al. 2021) . infection and trace all possible contacts in order to break the transmission paths, and also to 218 prevent more rapid spread of the pandemic. However, recognizing an asymptomatically (and 219 pre-symptomatic) infected individual is practically difficult (and sometimes impossible) since 220 they might not seek medical attention, which helps to identify their exposure to the disease 221 (Gao et al. 2021; Inbaraj, George, and Chandrasingh 2021) . As a result, relevant authorities 222 did not recommend absolute reliance on the morbidity and mortality cases identified through 223 RT-PCR since it is very likely to have potential under-reporting issues (Inbaraj, George, and 224 Chandrasingh 2021) . 225

Furthermore, to tackle this issue, the concerned authorities suggested that more 226 research should be done on population-based sero-epidemiological surveys to generate more 227 data that would help design the most effective control strategies ('World Health Organization. seroprevalence of COVID-19 in India to be 0.73% between May-June 2020 (Inbaraj, George, 235 and Chandrasingh 2021; Murhekar et al. 2020 ). Subsequently (i.e., around August-September 236 2020), most serosurveys estimated the seroprevalence of SARS-CoV-2 in India to be 7-10% 237 Inbaraj, George, and Chandrasingh 2021; Khan et al. 2020; Murhekar, 238 Bhatnagar, Selvaraju, et al. 2021; Murhekar, Bhatnagar, Thangaraj, et al. 2021) . In their 239 recent serosurvey study, Murhekar et al. estimated the overall seroprevalence of SARS-CoV-240 2 in India to be more than 24% (Murhekar, Bhatnagar, Thangaraj, et al. 2021) . 241

The epidemiological implications of SARS-CoV-2 seroprevalence are that it helps 242 identify whether herd immunity has been reached (due to vaccination or previous exposure to 243 the virus). It also helps to identify more cases, especially asymptomatically infected 244 individuals who do not usually show COVID-19 symptoms, to design the most effective 245 control strategies to mitigate the epidemics. High estimation of seroprevalence of COVID-19 246 would indicate that most of the population have been infected, and the herd immunity 247 threshold will likely be reached Kwok et al. 2021) . Hence, the control 248 efforts should be emphasized on recovering for the damages caused by this deadly virus, 249 which includes suspension of control and intervention programmes, immunization and 250 primary health care services for other infectious diseases; as well as rebuilding for better 251 socio-economic development. 252

Our study has some limitations. We employed serological data that used multiple and 253 mixing testing machines (Abbott and non-Abbott, e.g. Roche) to reconstruct an IAR and 254 estimate the seroprevalence of COVID-19 in large cities in India. The true situation is much 255 complicated than what we have considered. This could likely affect the actual estimation of 256 seroprevalence in these cities. Further, we considered only 12 Indian cities; thus, 257 interpretation for the overall scenarios has to be done with caution since new epidemiological 258 features of SAR-CoV-2 is being discovered every day. We rely on the confidence on the 259 COVID-19 death reporting. 260

The seroprevalence of COVID-19 in India did not usually alter by sex or age group. 262

This paper reconstructed the attack rate and estimated the seroprevalence of COVI-19 deaths 263 in 12 large Indian cities. We found a reasonable seropositivity rate to SARS-CoV-2 in most 264 cities, where Abbott was likely used. We recommend that further sero-epidemiological 265 studies and improved COVID mortality reporting couple with different existing control 266 strategies can effectively help in suppressing the COVID-19 morbidity and mortality in India 267 and beyond. Although we did not generate new data, we provide a way to connect data from 268 different sources (COVID-19 deaths and serological survey) which were treated separately in 269 previous studies. Hence the overall confidence on these data is enhanced and potential 270 inconsistence can be revealed. Serological data used in this work were taken from the following references, Maine et al, 279 2020 , Muecksch et al 2020 , Eberhardt et al 2020 , Kahre et al, 2020 Harris et al, 2020 . 280 Velumani et al. 2021 . The COVID-19 deaths data for Indian cities were obtained from 281 https://api.covid19india.org. 282

The authors declare that they have no competing interests. 284

The work described in this paper was partially supported by a grant from the Research Grants 286 compared with serological surveys (black curve with circles) in 12 Indian cities (Velumani et 408 al. 2021) . The attack rate (AR) is a monotone-increase function of time given its definition. 409

The seroprevalence is lower than the AR due to sensitivity which is less than 100% and 410 decays rapidly over time. We align the reconstructed seroprevalence and serological survey 411 to yield an IFR which is applied to both the reconstructed seroprevalence curve and the AR 412 

A mathematical model reveals the 305 influence of population heterogeneity on herd immunity to SARS-CoV-2

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay 310 for the Detection of Anti-SARS-CoV-2 IgG

A 312 systematic review of asymptomatic infections with COVID-19

High seroprevalence of COVID-19 infection in a large slum in South India; what 316 does it tell us about managing a pandemic and beyond?

Shazaad Ahmad, and Lorraine Stapley. 2021. 320 'Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a 321 cohort of public health workers

CoV-2 variant and reinfection in the resurgence of COVID-19 outbreaks in Manaus

326 'Seroprevalence of COVID-19 infection in a rural district of South India: A population-327 based seroepidemiological study

Kinetics 330 and seroprevalence of SARS-CoV-2 antibodies-a comparison of 3 different assays

Seroprevalence of SARS-CoV-2 specific IgG antibodies in District 335

northern India-a cross-sectional study

Will achieving herd immunity be a road 338 to success to end the COVID-19 pandemic?

Clinical and immunological assessment of 341 asymptomatic SARS-CoV-2 infections

The impact of 343 host resistance on cumulative mortality and the threshold of herd immunity for 344 SARS-CoV-2

Longitudinal characterization of the IgM and IgG humoral 348 response in symptomatic COVID-19 patients using the Abbott Architect

Systematic 351 review of empirical studies comparing the effectiveness of non-pharmaceutical 352 interventions against COVID-19

2021. 355 'Longitudinal serological analysis and neutralizing antibody levels in coronavirus 356 disease 2019 convalescent patients

Prevalence of SARS-CoV-2 infection in India: 360 Findings from the national serosurvey

364 Sabarinathan, and Smita Asthana. 2021. 'SARS-CoV-2 antibody seroprevalence in

findings from the second nationwide household 366 serosurvey

SARS-CoV-2 seroprevalence among the general 370 population and healthcare workers in India

The proportion of SARS-CoV-2 infections that are 373 asymptomatic: a systematic review

Can herd immunity save us from COVID-375 19?

Current 377 epidemiological and clinical features of COVID-19; a global perspective from China

Sze Hang Fu

Isaac Bogoch, Nico Nagelkerke, and Prabhat Jha. 2021. 'SARS-CoV

382 'World Health Organization. Coordinated global research roadmap: 2019 novel coronavirus

Proportion of asymptomatic 387 infection among COVID-19 positive persons and their transmission potential: A 388 systematic review and meta-analysis